BioMarin Pharmaceutical Stock Outlook Looks Promising
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy BMRN?
Source: Yahoo Finance
- Rating Adjustment: Piper Sandler revised BioMarin Pharmaceutical's price target from $122 to $84 on February 6 while maintaining an Overweight rating, indicating confidence in the company's future growth potential.
- Market Optimism: Barclays initiated coverage of BioMarin on January 27 with an Overweight rating and an $80 price target, anticipating significant tailwinds for the industry by 2026 and expressing a positive outlook for the biotech sector.
- Acquisition Catalyst: Canaccord Genuity upgraded BioMarin from Hold to Buy on January 20, adjusting the price target to $84, believing that the pending acquisition of Amicus will be a key driver for breaking the stock out of its recent trading range.
- Product Pipeline: BioMarin focuses on developing therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307, showcasing its ambition to translate genetic discoveries into new medicines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRN
Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.35 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 57.150
Low
60.00
Averages
87.35
High
120.00
Current: 57.150
Low
60.00
Averages
87.35
High
120.00
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioMarin Pharmaceutical Stock Outlook Looks Promising
- Rating Adjustment: Piper Sandler revised BioMarin Pharmaceutical's price target from $122 to $84 on February 6 while maintaining an Overweight rating, indicating confidence in the company's future growth potential.
- Market Optimism: Barclays initiated coverage of BioMarin on January 27 with an Overweight rating and an $80 price target, anticipating significant tailwinds for the industry by 2026 and expressing a positive outlook for the biotech sector.
- Acquisition Catalyst: Canaccord Genuity upgraded BioMarin from Hold to Buy on January 20, adjusting the price target to $84, believing that the pending acquisition of Amicus will be a key driver for breaking the stock out of its recent trading range.
- Product Pipeline: BioMarin focuses on developing therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307, showcasing its ambition to translate genetic discoveries into new medicines.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
BioMarin Expects Strong Sales for Voxzogo in Q4
- Voxzogo Sales Outlook: BioMarin anticipates that its rare disease drug Voxzogo will achieve its highest sales level in Q4 2024, as CFO Brian Mueller indicated during the Q3 earnings call, which is expected to drive revenue growth and bolster investor confidence.
- Guidance Adjustment: The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting optimistic expectations for Q4 performance, which may reduce the risk of negative surprises in earnings reports and further solidify market trust in the company.
- FDA Approval Catalyst: BioMarin expects to receive an FDA approval decision for Palynziq on February 28, 2026, which could provide new growth opportunities for the company, with potential EU approval also anticipated in the first half of the year.
- Competition Risks: Despite BioMarin's optimistic outlook for Voxzogo, management acknowledged potential competitive pressures that could impact market share in 2027, necessitating careful risk assessment by investors.
See More
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
See More
BioMarin Plans $850M Senior Unsecured Notes Offering
- Financing Plan: BioMarin has outlined an $850M offering of senior unsecured notes due 2034, aimed at supporting its upcoming acquisition, reflecting the company's proactive fundraising strategy in the capital markets.
- Loan Arrangements: The company also announced a new $2B senior secured term loan 'B' facility, alongside an $800M senior secured term loan 'A' facility and a $600M senior secured revolving credit facility, ensuring ample liquidity for the acquisition.
- Acquisition Deal: BioMarin has agreed to acquire rare disease drug developer Amicus Therapeutics for nearly $4.8B in an all-cash transaction, marking a strategic expansion in the rare disease sector that is expected to enhance its product portfolio and market competitiveness.
- Expense Management: The company plans to borrow up to $150M under the new revolving credit facility to cover acquisition-related fees and expenses, ensuring liquidity and smooth execution of the acquisition.
See More
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes
- Bond Offering Plan: BioMarin intends to offer $850 million in senior unsecured notes due in 2034, aimed at funding the upcoming acquisition of Amicus Therapeutics, thereby enhancing the company's financial flexibility.
- Loan Facility Expansion: The company is also launching a $2 billion senior secured Term Loan B facility, in addition to an $800 million Term Loan A facility and a $600 million revolving credit facility, ensuring ample financing for the acquisition.
- Clear Use of Proceeds: BioMarin plans to utilize the net proceeds from the bond issuance along with loans and cash to cover acquisition-related fees and expenses, ensuring a smooth transaction while mitigating financial risks.
- Compliance and Restrictions: The notes will not be registered under the Securities Act of 1933, with the offering limited to qualified institutional buyers, ensuring compliance and reducing market risks.
See More
BioMarin Pharmaceutical Stock Outlook Looks Promising
- Rating Adjustment: Piper Sandler revised BioMarin Pharmaceutical's price target from $122 to $84 on February 6 while maintaining an Overweight rating, indicating confidence in the company's future growth potential.
- Market Optimism: Barclays initiated coverage of BioMarin on January 27 with an Overweight rating and an $80 price target, anticipating significant tailwinds for the industry by 2026 and expressing a positive outlook for the biotech sector.
- Acquisition Catalyst: Canaccord Genuity upgraded BioMarin from Hold to Buy on January 20, adjusting the price target to $84, believing that the pending acquisition of Amicus will be a key driver for breaking the stock out of its recent trading range.
- Product Pipeline: BioMarin focuses on developing therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307, showcasing its ambition to translate genetic discoveries into new medicines.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
BioMarin Expects Strong Sales for Voxzogo in Q4
- Voxzogo Sales Outlook: BioMarin anticipates that its rare disease drug Voxzogo will achieve its highest sales level in Q4 2024, as CFO Brian Mueller indicated during the Q3 earnings call, which is expected to drive revenue growth and bolster investor confidence.
- Guidance Adjustment: The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting optimistic expectations for Q4 performance, which may reduce the risk of negative surprises in earnings reports and further solidify market trust in the company.
- FDA Approval Catalyst: BioMarin expects to receive an FDA approval decision for Palynziq on February 28, 2026, which could provide new growth opportunities for the company, with potential EU approval also anticipated in the first half of the year.
- Competition Risks: Despite BioMarin's optimistic outlook for Voxzogo, management acknowledged potential competitive pressures that could impact market share in 2027, necessitating careful risk assessment by investors.
See More
FDA Approves Zycubo for Pediatric Menkes Disease Treatment
- FDA Drug Approval: On January 13, 2026, Sentynl Therapeutics' Zycubo received FDA approval as the first treatment for pediatric patients with Menkes disease, representing a significant breakthrough in the treatment of rare neurodegenerative disorders and is expected to enhance patient quality of life.
- Food Labeling Reform: On January 21, 2026, the U.S. regulator issued a Request for Information aimed at improving gluten ingredient disclosure in foods, particularly focusing on allergic reactions to rye and barley, which could drive significant changes in food industry labeling transparency.
- Future Review Outlook: As February 2026 approaches, several drugs are set for FDA review, with the industry eagerly anticipating the regulatory outcomes, as successful approvals could present substantial market opportunities for related biotech firms.
- Biotech Stock Focus: The FDA's review decisions will directly impact the performance of biotech stocks, prompting investors to closely monitor the upcoming review results to assess market dynamics and investment strategies.
See More
BioMarin Plans $850M Senior Unsecured Notes Offering
- Financing Plan: BioMarin has outlined an $850M offering of senior unsecured notes due 2034, aimed at supporting its upcoming acquisition, reflecting the company's proactive fundraising strategy in the capital markets.
- Loan Arrangements: The company also announced a new $2B senior secured term loan 'B' facility, alongside an $800M senior secured term loan 'A' facility and a $600M senior secured revolving credit facility, ensuring ample liquidity for the acquisition.
- Acquisition Deal: BioMarin has agreed to acquire rare disease drug developer Amicus Therapeutics for nearly $4.8B in an all-cash transaction, marking a strategic expansion in the rare disease sector that is expected to enhance its product portfolio and market competitiveness.
- Expense Management: The company plans to borrow up to $150M under the new revolving credit facility to cover acquisition-related fees and expenses, ensuring liquidity and smooth execution of the acquisition.
See More
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes
- Bond Offering Plan: BioMarin intends to offer $850 million in senior unsecured notes due in 2034, aimed at funding the upcoming acquisition of Amicus Therapeutics, thereby enhancing the company's financial flexibility.
- Loan Facility Expansion: The company is also launching a $2 billion senior secured Term Loan B facility, in addition to an $800 million Term Loan A facility and a $600 million revolving credit facility, ensuring ample financing for the acquisition.
- Clear Use of Proceeds: BioMarin plans to utilize the net proceeds from the bond issuance along with loans and cash to cover acquisition-related fees and expenses, ensuring a smooth transaction while mitigating financial risks.
- Compliance and Restrictions: The notes will not be registered under the Securities Act of 1933, with the offering limited to qualified institutional buyers, ensuring compliance and reducing market risks.
See More
